Enzalutamide + Gemcitabine + Nab-paclitaxel

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

May 22, 2014 → Oct 7, 2019

NCT ID

NCT02138383

About Enzalutamide + Gemcitabine + Nab-paclitaxel

Enzalutamide + Gemcitabine + Nab-paclitaxel is a phase 1 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02138383. Target conditions include Pancreatic Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Cancer were approved

Approved (9) Terminated (4) Active (11)

✅DalteparinEisaiApproved

✅CREONAbbVieApproved

✅Pancrelipase + PlaceboAbbVieApproved

✅Pancrelipase CapsulesAbbVieApproved

✅Chromogranin ANovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02138383	Phase 1	Completed	May 22, 2014	Oct 7, 2019	Pancreatic Cancer

Competing Products

20 competing products in Pancreatic Cancer

See all competitors

Product	Company	Stage	Hype Score
CD40 agonist mitazalimab in combination with chemotherapy	Alligator Bioscience AB	Phase 1/2	26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	18
pemetrexed	Eli Lilly	Phase 2	35
mFOLFIRINOX + Ramucirumab	Eli Lilly	Phase 2	35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	29
enzastaurin + gemcitabine	Eli Lilly	Phase 2	35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4	Eli Lilly	Phase 1	29
Ramucirumab	Eli Lilly	Phase 1/2	32
GEMZAR + ALIMTA	Eli Lilly	Phase 3	40
CS-1008 (humanized anti-DR5 antibody) + gemcitabine	Daiichi Sankyo	Phase 2	35
exatecan mesylate	Daiichi Sankyo	Phase 2	35
exatecan mesylate + gemcitabine hydrochloride	Daiichi Sankyo	Phase 3	40
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
AGS-1C4D4 + gemcitabine	Astellas Pharma	Phase 2	35
erlotinib + gemcitabine + nab-paclitaxel	Astellas Pharma	Phase 1	29
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 1	29
AGS-1C4D4 + Gemcitabine	Astellas Pharma	Phase 2	35
Tarceva (erlotinib HCl, OSI-774)	Astellas Pharma	Phase 3	40